References
- Chapman A, Dixon S, Andrews D, et al. Clinical efficacy and cost-effectiveness of Outpatient Parenteral Antibiotic Therapy (OPAT): a UK perspective. J Antimicrob Chemother [Internet]. 2009;64(6):1316–1324. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=19767623
- Chapman A. Outpatient parenteral antimicrobial therapy. BMJ [Internet]. 2013;346:585. Available from: http://www.bmj.com/highwire/filestream/638032/field_highwire_article_pdf/0/bmj.f1585
- Tice A, Rehm S, Dalovisio J, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis [Internet]. 2004;38(12):1651–1672. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15227610
- Mackenzie M, Rae N, Nathwani D. Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: a review of the last decade. Int J Antimicrob Agents [Internet]. 2014;43(1):7–16. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L52852206
- Esposito S, Noviello S, Leone S, et al. Outpatient Parenteral Antibiotic Therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents [Internet]. 2004;24(5):473–478. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15519480
- Psaltikidis E, Silva E, Bustorff-Silva J, et al. Economic evaluation of outpatient parenteral antimicrobial therapy: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2017;17(4):355–375.
- Minton J, Murray C, Meads D, et al. The Community Intravenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy. Heal Serv Deliv Res. 2017;5(6):1–271.
- Durojaiye O, Bell H, Andrews D, et al. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. Int J Antimicrob Agents. 2018;51:26–32.
- Chapman A, Seaton R, Cooper M, et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother. 2012;67:1053–1062.
- Esposito S, Ianniello F, Noviello S, et al. Outpatient Parenteral Antibiotic Therapy (OPAT): the Italian registry. Infez Med [Internet]. 2002;10(3):169–175. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L35167941
- Bryant P, Katz N. Inpatient versus outpatient parenteral antibiotic therapy at home for acute infections in children: a systematic review. Lancet Infect Dis. 2018;18(2):45–54.
- Oliveira P, Felix C, Carvalho V, et al. Outpatient parenteral antimicrobial therapy for orthopedic infections – a successful public healthcare experience in Brazil. Braz J Infect Dis. 2016;20(3):272–275.
- Psaltikidis E, Resende M, Mattos K, et al. Identifying inpatients to outpatient parenteral antimicrobial therapy: a point prevalence study. Value Health. 2018;20(9):A927.
- Oliveira P, Carvalho V, Cimerman S, et al. Diretrizes Brasileiras para terapia antimicrobiana parenteral ambulatorial group. Recommendations for outpatient parenteral antimicrobial therapy in Brazil. Braz J Infect Dis. 2017;21(6):648–655.
- Lopardo G. Management of endocarditis: outpatient parenteral antibiotic treatment in Argentina. Chemotherapy. 2001;47(Suppl 1):24–32.
- Peña A, Zambrano A, Alvarado M, et al. Evaluación de la efectividad, seguridad y costos del tratamiento antimicrobiano intravenoso ambulatorio (TAIA) vs hospitalizado en infección urinaria en pediatría [Evaluation of the effectiveness, safety and costs of outpatient intravenous antimicrobial t. Rev Chil Infectol. 2013;30(4):426–434.
- Aguilar E. Experience and outcomes after a year of implementation of a program for outpatient parenteral antimicrobial therapy in a tertiary care hospital in Mexico City. Poster session presented at: ID Week; 2015 Oct 7–11; San Diego, CA.
- Seaton R, Gonzalez-Ramallo V, Prisco V, et al. Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience. Int J Antimicrob Agents [Internet]. 2013;41(5):468–472. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L52479843
- Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.
- Brasil. Ministério da Saúde. Secretaria de Ciência Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: diretriz de avaliação econômica [Methodological guideline: economic evaluation of health technologies]. 2nd ed. Brasília: Ministério da Saúde; 2014.
- Ribeiro A, Neyeloff J, Itria A, et al. Methodological guidelines for economic evaluation studies of health technologies in Brazil. J Bras Econ Saúde. 2016;8(3):174–184.
- Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
- Brasil. Ministério da Saúde. Secretaria de Ciência Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: elaboração de pareceres técnico-científicos [Methodological guideline: elaborating rapid HTAs]. 4th ed. Brasília: Ministério da Saúde; 2014.
- The British Society for Antimicrobial Chemotherapy (BSAC). OPAT National Outcomes Registry (NORS). User Guide for NORS (Adult & Paediatric) [Internet]. 2015. [cited 2018 May 12] Available from: http://www.e-opat.com/wp-content/uploads/2016/04/NORS-user-guide_October-2015.pdf
- Weinstein M, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12(Suppl 1):S5–S9.
- QALY Brasil. Estudo QALY Brasil [QALY Brazil study] [Internet]. 2012. [cited 2018 Mar 10] Available from: http://natsinc.org/wpress/euroqol/?page_id=767
- Santos M, Cintra M, Monteiro A, et al. Brazilian valuation of EQ-5D-3L health states: results from a saturation study. Med Decis Mak. 2016;36(2):253–263.
- Hospital de Clínicas da Universidade Estadual de Campinas (Unicamp). Protocolo TEAPA HC-Unicamp [OPAT HC-Unicamp protocol] [Internet]. 2015. [cited 2017 Dec 19] Available from: https://intranet.hc.unicamp.br/sites/default/files/users/eliene/MANUALPARATERAPIAANTIMICROBIANAPARENTERALAMBULATORIALFINAL.pdf
- Frick K. Micro-costing quantity data collection methods. Med Care. 2009;47(7 Suppl 1):S76–S81.
- Charles J, Edwards R, Bywater T, et al. Micro-costing in public health economics: steps towards a standardized framework, using the incredible years toddler parenting program as a worked example. Prev Sci. 2013;14:377–389.
- Silva E, Silva M, Pereira M. Identifying, measuring and valuing health costs. Epidemiol Serv Saúde. 2016;25(6):437–439.
- U.S.Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) (v4.03) [Internet]. 2010. [cited 2017 Jan 4] Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
- Ramsey S, Willke R, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II—an ISPOR good research practices task force report. Value Health. 2015;18:161–172.
- Hendriks M, Kundu P, Boers A, et al. Step-by-step guideline for disease-specific costing studies in low- and middle-income countries: a mixed methodology. Glob Heal Action [Internet]. 2014;7(23573):1–10.
- Wolter JM, Cagney RA, McCormack JG. A randomized trial of home vs hospital intravenous antibiotic therapy in adults with infectious diseases. J Infect. 2004;48(3):263–268.
- Yong C, Fisher D, Sklar G, et al. A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective. Int J Antimicrob Agents [Internet]. 2009;33(1):46–51. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L50283193
- Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.
- Lacroix A, Revest M, Patrat-Delon S, et al. Outpatient parenteral antimicrobial therapy for infective endocarditis: a cost-effective strategy. Med Mal Infect [Internet]. 2014;44(7):327–330. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L53233542
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) [São Paulo Research Foundation]. Processo 14/50045-3. Terapia antimicrobiana parenteral ambulatorial baseada em hospital-dia, como ferramenta custo-efetiva de desospitalização no Sistema Único de Saúde [Internet]. 2015. [cited 2017 Jan 17]. Available from: http://www.bv.fapesp.br/pt/auxilios/86784/terapiaantimicrobiana-%0Aparenteral-ambulatorial-baseada-em-hospital-diacomo-ferramenta-custo-efetiv/%0A
- Wai AO, Frighetto L, Marra CA, et al. Cost analysis of an adult Outpatient Parenteral Antibiotic Therapy (OPAT) programme. A Canadian teaching hospital and ministry of health perspective. Pharmacoeconomics [Internet]. 2000;18(5):451–457. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L30825703
- González-Ramallo V, Mirón-Rubio M, Mujal A, et al. Costs of Outpatient Parenteral Antimicrobial Therapy (OPAT) administered by hospital at home units in Spain. Int J Antimicrob Agents. 2017;50:114–118.
- Mitchell E, Murray C, Meads D, et al. Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review. BMJ Open. 2017;7:e013560.
- Vargas-Palacios A, Meads D, Twiddy M, et al. Cost-effectiveness of outpatient parenteral antibiotic therapy: a simulation modelling approach. J Antimicrob Chemother. 2017;72:2392–2400.
- Chen X. Challenges in responses to syphilis epidemic. Lancet Infect Dis. 2017;17(8):793–794.
- Gomes N, Meier D, Pieri F, et al. Prevalence and factors associated with syphilis in a reference center. Rev Soc Bras Med Trop. 2017;50(1):27–34.
- Brasil. Ministério da Saúde. Nota informativa conjunta no 68/2016 DDAHV/SVS/MS e DAPES/SAS/MS [Internet]. 2016. [cited 2017 Jul 4] Available from: file:///C:/Users/Admin/Downloads/nota_informativa_conjunta_ddahv_e_dapes_tratamento_66915.pdf
- Graf von der Schulenburg J, Greiner W, Klettke U, et al. Ökonomische aspekte der behandlung zystischer fibrose mit chronischer pulmonaler pseudomonasinfektion [Economic aspects of treatment of cystic fibrosis with chronic pulmonal pseudomonas infection]. Med Klin. 1997;92(10):626–629.
- Goodfellow A, Wai A, Frighetto L, et al. Quality-of-life assessment in an outpatient parenteral antibiotic program. Ann Pharmacother [Internet]. 2002;36(12):1851–1855. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L35429553
- Madaline T, Nori P, Mowrey W, et al. Bundle in the Bronx: impact of a transition-of-care outpatient parenteral antibiotic therapy bundle on all-cause 30-day hospital readmissions. Open Forum Infect Dis. 2017;4(2):ofx097.
- Means L, Bleasdale S, Sikka M, et al. Predictors of hospital readmission in patients receiving outpatient parenteral antimicrobial therapy. Pharmacotherapy. 2016;36(8):934–939.
- Ravelingien T, Buyle F, Deryckere S, et al. Optimization of a model of out-of-hospital antibiotic therapy (OPAT) in a Belgian university hospital resulting in a proposal for national implementation. Acta Clin Belg. 2016;19:1–6.
- Al Ansari A, Al Alawi S, Al Qahtani M, et al. Outpatient parenteral antimicrobial terapy (OPAT) in the Kingdom of Bahrain: efficacy, patient satisfaction and cost effectiveness. Open Infect Dis J [Internet]. 2013;7;90–95. Available from: http://benthamopen.com/toidj/articles/V007/90TOIDJ.pdf
- Teuffel O, Amir E, Alibhai S, et al. Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. Br J Cancer [Internet]. 2011 Jan;104(9):1377–1383. Available from: http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22011000889
- Kameshwar K, Karahalios A, Janus E, et al. False economies in home-based parenteral antibiotic treatment: a health-economic case study of management of lower-limb cellulitis in Australia. J Antimicrob Chemother. 2016;71:830–835.